The final analysis of the CLL14 study, conducted alongside the German CLL Study Group, highlights the durability of the combination therapy for patients with coexisting medical conditions. Data indicate a median time to next treatment of approximately 7.6 years, offering an extended period of remission without the need for additional specific therapy.

After a median follow-up of 9.2 years, the venetoclax-based regimen demonstrated superior progression-free survival compared to the standard combination of obinutuzumab and chlorambucil. Patients receiving the venetoclax combination achieved a median progression-free survival of 6.4 years, compared to 3.2 years for the control group. The study confirms that the fixed-duration approach remains a viable option for those managing complex health profiles, with the most frequent Grade 3 adverse events including neutropenia, thrombocytopenia, and pneumonia.